Inflammatory arthritis, including rheumatoid arthritis and ankylosing spondylitis
Conditions
Interventions
Recombinant Human Tumor Necrosis Factor Receptor–Fc Fusion Protein Injection Exposure group:NA
Sponsors
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Obtain a prescription for recombinant human type II tumor necrosis factor receptor antibody fusion protein injection; 2. Aged 18 years or older; 3. Fulfilling the diagnostic criteria for rheumatoid arthritis as defined by the American College of Rheumatology and the European Alliance of Associations for Rheumatology, or for ankylosing spondylitis as defined by the 1984 revised New York criteria of the American College of Rheumatology, and providing consent to participate in this study;
Exclusion criteria
Exclusion criteria: 1. Concurrent participation in any other interventional drug trial; 2. Life expectancy less than six months; 3. Any other condition that the investigator deems incompatible with study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of patients achieving clinical remission or low disease activity; | — |
Secondary
| Measure | Time frame |
|---|---|
| 12-month drug retention rate;Bath Ankylosing Spondylitis Functional Index;rate of adverse events leading to discontinuation;Health Assessment Questionnaire Disability Index;rate of SAEs;Rate of AEs; | — |
Countries
China
Contacts
Public ContactHouwen Lin
Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed